Portal de Periódicos da CAPES

Autoantibodies Against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis

2010; Lippincott Williams & Wilkins; Volume: 42; Issue: 2 Linguagem: Inglês

10.1161/strokeaha.110.592121

1524-4628

Gabriela Cesarman‐Maus, Carlos Cantú‐Brito, Fernando Barinagarrementería, Rosario Villa, Elba Reyes, Jorge Sánchez‐Guerrero, Katherine A. Hajjar, Ethel Garcia Latorre,

Cell Adhesion Molecules Research

Background and Purpose— Cerebral venous thrombosis (CVT) may be a manifestation of underlying autoimmune disease. Antibodies against annexin A2 (anti-A2Ab) coincide with antiphospholipid syndrome, in which antiphospholipid antibodies (aPLA) are associated with thrombosis in any vascular bed. Annexin A2, a profibrinolytic receptor and binding site for β2-glycoprotein-I, the main target for aPLA, is highly expressed on cerebral endothelium. Here we evaluate the prevalence of anti-A2Ab in CVT. Methods— Forty individuals with objectively documented CVT (33 women and 7 men) and 145 healthy controls were prospectively studied for hereditary and acquired prothrombotic risk factors, classical aPLA, and anti-A2Ab. Results— One or more prothrombotic risk factors were found in 85% of CVT subjects, (pregnancy/puerperium in 57.5%, classical aPLA in 22.5%, and hereditary procoagulant risk factors in 17.5%). Anti-A2Ab (titer >3 SD) were significantly more prevalent in patients with CVT (12.5%) than in healthy individuals (2.1%, P <0.01, OR, 5.9). Conclusions— Anti-A2Ab are significantly associated with CVT and may define a subset of individuals with immune-mediated cerebral thrombosis.